Status:
COMPLETED
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Prostatic Neoplasm
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The current study involves a novel and aggressive therapeutic approach for patients' prostate cancer. In addition, the investigators propose to administer hormonal therapy to patients with an especial...
Eligibility Criteria
Inclusion
- Patients with pathologically proven prostate cancer
- No evidence of distant metastases (M0) on physical examination, bone scan
- ECOG PS 0,1,2
- Adequate organ function as evidenced by:
- Hemoglobin \> 10.0 gm/dl
- White blood count \> 3000/mcL
- Platelet count \> 90,000/mcL
- AST \< 2x normal
- Age \> 18 years
- Patients can not be allergic to Leuprolide or Goserelin if the pretreatment PSA \> 20, Gleason Score \> 8, T3/4, or N1 disease
- Written informed consent
- We anticipate enrolling at least 50 patients per year, which would bring accrual to projected total of 100 patients in 2 years
Exclusion
- None
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00956228
Start Date
October 1 2006
End Date
December 1 2007
Last Update
February 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States